Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2010 TO 2019]"
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Japan%22&type=Subject
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Japan%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=collection%3ACTG&lookfor=%22Japan%22&type=Subject
PubPharm (14)
1
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
2
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2017
Wird geladen...
3
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2013
Wird geladen...
4
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2013
Wird geladen...
5
A study to evaluate the efficacy and safety of the study drug DP-b99 in patients who suffer from acute ischemic stroke : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
6
A study to evaluate the efficacy and safety of the study drug DP-b99 in patients who suffer from acute ischemic stroke : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
7
A study to evaluate the efficacy and safety of the study drug DP-b99 in patients who suffer from acute ischemic stroke : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
8
A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
9
A study to evaluate the efficacy and safety of the study drug DP-b99 in patients who suffer from acute ischemic stroke : A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
10
A double blind, randomized, placebo-controlled, parallel group,multicenter Phase 3 pivotal study to assess the safety and efficacy of1mg/kg/day intravenous DP-b99 over 4 consecutive days versusplacebo when initiated within nine hours of acute ischemic stroke onset. - MACSI : A double blind, randomized, placebo-controlled, parallel group,multicenter Phase 3 pivotal study to assess the safety and efficacy of1mg/kg/day intravenous DP-b99 over 4 consecutive days versusplacebo when initiated within nine hours of acute ischemic stroke onset. - MACSI
enthalten in:
WHO International Clinical Trials Registry Platform
| 2012
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Erscheinungsjahr: 2010-2019
Medienart
14
Aufsätze
14
E-Artikel
14
E-Ressourcen
Zeitschriftentitel
14
WHO International Clinical Trials Registry Plat...
Thema
14
610
14
Recruitment Status: Not yet recruiting
14
Study Type: Interventional
6
Medical Condition: Acute Ischemic StrokeStroke ...
4
Medical Condition: Acute Ischemic StrokeStroke ...
2
Medical Condition: Acute Ischemic StrokeStroke ...
2
Medical Condition: Acute Ischemic StrokeStroke ...
2
Phase: Phase 3
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2010-2019
2
2017
2
2013
10
2012
Erscheinungsjahr(e)
Von:
Bis:
Sprache
14
Englisch
Haven't found what you're looking for?
Wird geladen...